These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33884654)

  • 1. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease.
    Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK
    J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3
    Lee SH; Shin DJ; Kim Y; Kim CJ; Lee JJ; Yoon MS; Uong TNT; Yu D; Jung JY; Cho D; Jung BG; Kim SK; Suh GH
    Front Immunol; 2018; 9():841. PubMed ID: 29755462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg(-/-) (NSG) Mice.
    Gregoire-Gauthier J; Fontaine F; Benchimol L; Nicoletti S; Selleri S; Dieng MM; Haddad E
    Biol Blood Marrow Transplant; 2015 May; 21(5):821-8. PubMed ID: 25596424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice.
    Xun C; Brown SA; Jennings CD; Henslee-Downey PJ; Thompson JS
    Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
    Batatinha H; Diak DM; Niemiro GM; Baker FL; Smith KA; Zúñiga TM; Mylabathula PL; Seckeler MD; Lau B; LaVoy EC; Gustafson MP; Katsanis E; Simpson RJ
    Front Immunol; 2023; 14():1067369. PubMed ID: 37077913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
    Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.
    Shin DJ; Park JY; Jang YY; Lee JJ; Lee YK; Shin MG; Jung JY; Carson WE; Cho D; Kim SK
    Vet Immunol Immunopathol; 2013 Jun; 153(3-4):249-59. PubMed ID: 23548866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
    Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.
    Trujillo-Ocampo A; Cho HW; Herrmann AC; Ruiz-Vazquez W; Thornton AB; He H; Li D; Qazilbash MA; Ma Q; Porcelli SA; Shpall EJ; Molldrem J; Im JS
    Cytotherapy; 2018 Aug; 20(8):1089-1101. PubMed ID: 30076070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
    Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
    Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
    Baker J; Verneris MR; Ito M; Shizuru JA; Negrin RS
    Blood; 2001 May; 97(10):2923-31. PubMed ID: 11342413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.